AK129 + AK117

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Classic Hodgkin Lymphoma

Conditions

Classic Hodgkin Lymphoma

Trial Timeline

Jan 17, 2025 → Feb 1, 2028

NCT ID

NCT06642792

About AK129 + AK117

AK129 + AK117 is a phase 1/2 stage product being developed by Akeso for Classic Hodgkin Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06642792. Target conditions include Classic Hodgkin Lymphoma.

What happened to similar drugs?

0 of 3 similar drugs in Classic Hodgkin Lymphoma were approved

Approved (0) Terminated (1) Active (2)

🔄Camrelizumab + Investigator's choice of ChemotherapyJiangsu Hengrui MedicinePhase 3

🔄Sintilimab + Carboplatin + Etoposide + Ifosfamide + Placebo + Carboplatin + Etoposide + IfosfamideInnovent BiologicsPhase 3

❌Tislelizumab + Salvage ChemotherapyBeOne MedicinesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06642792	Phase 1/2	Recruiting	Jan 17, 2025	Feb 1, 2028	Classic Hodgkin Lymphoma

Competing Products

15 competing products in Classic Hodgkin Lymphoma

See all competitors

Product	Company	Stage	Hype Score
Camrelizumab + Investigator's choice of Chemotherapy	Jiangsu Hengrui Medicine	Phase 3	36
Sabestomig (AZD7789)	AstraZeneca	Phase 1	29
THOR-707 + Pembrolizumab	Merck	Phase 2	27
Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin	Merck	Phase 2	42
Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone	Merck	Phase 2	35
Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate	Merck	Phase 2	31
Carboplatin + Etoposide + Ifosfamide + Pembrolizumab	Merck	Phase 2	31
Pembrolizumab (+) Berahyaluronidase alfa	Merck	Phase 2	39
Panobinostat	Novartis	Phase 2	35
PD1	Innovent Biologics	Phase 2	35
Sintilimab + Carboplatin + Etoposide + Ifosfamide + Placebo + Carboplatin + Etoposide + Ifosfamide	Innovent Biologics	Phase 3	36
Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine	Bristol Myers Squibb	Phase 1	33
Nivolumab + Ipilimumab	Bristol Myers Squibb	Phase 2	31
Tislelizumab + Salvage Chemotherapy	BeOne Medicines	Phase 3	29
GEN3017	Genmab	Phase 1/2	21